Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBS102
- Development stage
- Preclinical
- Lead developer
- CellmAbs
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CBS102 is a preclinical-stage cellular therapy being developed by CellmAbs for the treatment of cancer. The therapy is engineered to target cancer-specific glycans, which are unique post-translational modifications found on the surface of tumor cells but absent or significantly reduced in healthy tissues. By focusing on these glycan targets, CBS102 aims to provide a highly selective treatment modality that minimizes off-target toxicity. The program is part of CellmAbs' broader pipeline of glycan-targeted immunotherapies, which leverages proprietary technology to identify and target tumor-associated carbohydrate antigens (TACAs).
Beyond the preview
Go deeper on CBS102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBS102.